Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Moving towards Normalization of haemostasis and health equity: Evolving treatment goals for haemophilia A

PA. Holme, J. Blatný, P. Chowdary, R. Lassila, N. O'Connell, C. Hermans, MT. Álvarez Román, C. Négrier, A. Coppola, J. Oldenburg

. 2024 ; 30 (5) : 1109-1114. [pub] 20240710

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25004130

Grantová podpora
Sobi

BACKGROUND: Treatment options for people with haemophilia are evolving at a rapid pace and a range of prophylactic treatment options using various technologies are currently available, each with their own distinct safety and efficacy profile. TREATMENT GOALS: The access to replacement therapy and prophylaxis has driven a dramatic reduction in mortality and resultant increase in life expectancy. Beyond this, the abolition of bleeds and preservation of joint health represent the expected, but rarely attained, goals of haemophilia treatment and care. These outcomes also do not address the complexity of health-related quality of life impacted by haemophilia and its treatment. CONCLUSION: Capitalizing on the major potential of therapeutic innovations, 'Normalization' of haemostasis, as a concept, should include the aspiration of enabling individuals to live as normal a life as possible, free from haemophilia-imposed limitations. To achieve this-being supported by the data reviewed in this manuscript-the concept of haemostatic and life Normalization needs to be explored and debated within the wider multidisciplinary teams and haemophilia community.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25004130
003      
CZ-PrNML
005      
20250206105943.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/hae.15031 $2 doi
035    __
$a (PubMed)38986684
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Holme, Pål André $u Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
245    10
$a Moving towards Normalization of haemostasis and health equity: Evolving treatment goals for haemophilia A / $c PA. Holme, J. Blatný, P. Chowdary, R. Lassila, N. O'Connell, C. Hermans, MT. Álvarez Román, C. Négrier, A. Coppola, J. Oldenburg
520    9_
$a BACKGROUND: Treatment options for people with haemophilia are evolving at a rapid pace and a range of prophylactic treatment options using various technologies are currently available, each with their own distinct safety and efficacy profile. TREATMENT GOALS: The access to replacement therapy and prophylaxis has driven a dramatic reduction in mortality and resultant increase in life expectancy. Beyond this, the abolition of bleeds and preservation of joint health represent the expected, but rarely attained, goals of haemophilia treatment and care. These outcomes also do not address the complexity of health-related quality of life impacted by haemophilia and its treatment. CONCLUSION: Capitalizing on the major potential of therapeutic innovations, 'Normalization' of haemostasis, as a concept, should include the aspiration of enabling individuals to live as normal a life as possible, free from haemophilia-imposed limitations. To achieve this-being supported by the data reviewed in this manuscript-the concept of haemostatic and life Normalization needs to be explored and debated within the wider multidisciplinary teams and haemophilia community.
650    12
$a hemofilie A $x farmakoterapie $x terapie $7 D006467
650    _2
$a lidé $7 D006801
650    12
$a hemostáza $x účinky léků $7 D006487
650    12
$a rovnost ve zdraví $7 D000069576
650    _2
$a kvalita života $7 D011788
650    _2
$a cíle $7 D006040
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Blatný, Jan $u Hospital Bory, Bratislava, Slovakia $u Masaryk University, Brno, Czech Republic
700    1_
$a Chowdary, Pratima $u Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London, London, UK $1 https://orcid.org/0000000201351051
700    1_
$a Lassila, Riitta $u Coagulation Disorders Unit, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Research Program Unit in Systems Oncology, University of Helsinki, Helsinki, Finland $1 https://orcid.org/0000000219113094
700    1_
$a O'Connell, Niamh $u National Coagulation Centre, St James's Hospital, Dublin, Ireland and Trinity College Dublin, Dublin, Ireland
700    1_
$a Hermans, Cédric $u Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques universitaires Saint-Luc, Catholic University of Louvain (UCLouvain), Louvain, Belgium
700    1_
$a Álvarez Román, María Teresa $u Department of Hematology, La Paz University Hospital-IdiPaz, Autonomous University, Madrid, Spain $1 https://orcid.org/0000000332964288
700    1_
$a Négrier, Claude $u UR4609 Hémostase & Thrombose, University Lyon 1, Lyon, France $1 https://orcid.org/000000022905055X
700    1_
$a Coppola, Antonio $u Regional Reference Centre for Inherited Bleeding Disorders, University Hospital of Parma, Parma, Italy $1 https://orcid.org/000000033697706X
700    1_
$a Oldenburg, Johannes $u Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany $1 https://orcid.org/0000000215854100
773    0_
$w MED00001964 $t Haemophilia $x 1365-2516 $g Roč. 30, č. 5 (2024), s. 1109-1114
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38986684 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206105938 $b ABA008
999    __
$a ok $b bmc $g 2263714 $s 1240137
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 30 $c 5 $d 1109-1114 $e 20240710 $i 1365-2516 $m Haemophilia $n Haemophilia $x MED00001964
GRA    __
$p Sobi
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace